867257-26-9
867257-26-9
Chemical Structure
Tecarfarin
Synonym(s): ATI-5923
- CAS No.: 867257-26-9
- Formula:C21H14F6O5
- Molecular Weight:460.32
IUPAC Name: 1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl 4-((4-hydroxy-2-oxo-2H-chromen-3-yl)methyl)benzoate
InChIKey: QFLNTQDOVCLQKW-UHFFFAOYSA-N
SMILES: O=C(OC(C(F)(F)F)(C)C(F)(F)F)C1=CC=C(CC2=C(O)C3=CC=CC=C3OC2=O)C=C1
Biological Activity: Tecarfarin (ATI-5923) is an orally active and non-competitive vitamin K epoxide reductase (VKOR) antagonist, and impairs the activation of the vitamin K-dependent clotting factors II, VII, IX and X[1]. Tecarfarin has the antithrombotic activity [2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tecarfarin | 98.65% | Tecarfarin (ATI-5923) is an orally active and non-competitive vitamin K epoxide reductase (VKOR) antagonist, and impairs the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Tecarfarin has the antithrombotic activity . | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tecarfarin (Standard) | ≥98% | Tecarfarin (ATI-5923) (Standard) is the analytical standard of Tecarfarin. This product is intended for research and analytical applications. Tecarfarin is an orally active VKOR inhibitor with an IC50 of 0.67 μM against VKORC1. Tecarfarin blocks the post-translational modification of vitamin K-dependent coagulation factors II, VII, IX and X, reducing their levels and activities. Tecarfarin prolongs prothrombin time, attenuates venous and arterial thrombosis, increases ear incision bleeding volume, and exerts reversible anticoagulant effects. Tecarfarin is applicable to research related to arterial and venous thrombosis as well as other diseases requiring anticoagulation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tecarfarin-13C,d3 | Tecarfarin-13C,d3 (ATI-5923-13C,d3) is 13C labeled Tecarfarin. Tecarfarin is an orally active VKOR inhibitor with an IC50 of 0.67 μM against VKORC1. Tecarfarin blocks the post-translational modification of vitamin K-dependent coagulation factors II, VII, IX and X, reducing their levels and activities. Tecarfarin prolongs prothrombin time, attenuates venous and arterial thrombosis, increases ear incision bleeding volume, and exerts reversible anticoagulant effects. Tecarfarin is applicable to research related to arterial and venous thrombosis as well as other diseases requiring anticoagulation. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hobl EL, et al. Tecarfarin: A Novel Vitamin K Antagonist. Thromb Haemost. 2017 Nov;117(11):2009-2011. [Content Brief]
- [2]. Bowersox SS, et al. Antithrombotic activity of the novel oral anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in animal models. Thromb Res. 2010 Nov;126(5):e383-8. [Content Brief]
